Azoulay Salomon 4

What Happened
Azoulay Salomon, Chief Medical Officer of MBX Biosciences (MBX), sold 231 shares of company stock on May 6, 2026, for gross proceeds of approximately $6,824. The sale was reported as an open market/private sale (transaction code S) and reflects a routine sell-to-cover to satisfy tax obligations related to the vesting of restricted stock units.

Key Details

• Transaction date: May 6, 2026. Form 4 filed: May 8, 2026 (timely within the two-business-day window).
• Shares sold: 231 shares; reported weighted-average price: $29.54; aggregate proceeds ≈ $6,824.
• Price range for the aggregate sales: $29.23 to $29.88 (weighted average reported; detailed per-price breakdown available on request per footnote).
• Reason reported (footnote): Mandatory sell-to-cover to cover taxes upon RSU vesting (tax withholding).
• Shares owned after transaction: not specified in the provided filing.
• Transaction codes/notes: S = sale; F (tax withholding) applicable as described in footnote.

Context
Sell-to-cover transactions are routine tax-related disposals that do not necessarily indicate an executive's view on the company's prospects. The filing discloses this was done to satisfy tax obligations connected to RSU vesting and provides a weighted-average sale price and range for the aggregate participant sales.